ICU Medical, Inc. (ICUI)

ICU Medical Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	2,257	2,259	2,280	1,316	1,271	1,266
Revenue Growth (YoY)	-2.10%	-0.92%	73.21%	3.56%	0.38%	-9.56%
Cost of Revenue	1,524	1,519	1,582	824.82	809.51	794.34
Gross Profit	733.08	739.87	697.76	491.49	461.5	471.86
Selling, General & Admin	611.78	606.69	608.35	302.58	283.95	276.98
Research & Development	87.43	85.34	92.98	47.5	42.95	48.61
Other Operating Expenses	46.35	41.26	71.42	18.16	27.43	86.31
Operating Expenses	745.55	733.3	772.75	368.25	354.34	411.9
Operating Income	-12.48	6.58	-74.99	123.25	107.16	59.96
Interest Expense / Income	96.48	95.22	66.38	-1.98	-1.92	0.55
Other Expense / Income	-7.28	-10.34	-26.96	2.04	11.59	-55.3
Pretax Income	-101.68	-78.3	-114.41	123.19	97.49	114.71
Income Tax	-42.36	-48.64	-40.12	20.05	10.62	13.67
Net Income	-59.31	-29.66	-74.29	103.14	86.87	101.04
Net Income Growth	-	-	-	18.72%	-14.02%	250.90%
Shares Outstanding (Basic)	24	24	24	21	21	21
Shares Outstanding (Diluted)	24	24	24	22	22	22
Shares Change	0.87%	0.93%	9.58%	0.88%	0.21%	-0.26%
EPS (Basic)	-2.45	-1.23	-3.11	4.86	4.16	4.90
EPS (Diluted)	-2.45	-1.23	-3.11	4.74	4.02	4.69
EPS Growth	-	-	-	17.91%	-14.29%	252.63%
Free Cash Flow	76.9	74.03	-160.47	186.59	128.54	-4.09
Free Cash Flow Per Share	3.17	3.07	-6.72	8.80	6.15	-0.20
Gross Margin	32.48%	32.75%	30.60%	37.34%	36.31%	37.27%
Operating Margin	-0.55%	0.29%	-3.29%	9.36%	8.43%	4.74%
Profit Margin	-2.63%	-1.31%	-3.26%	7.84%	6.83%	7.98%
Free Cash Flow Margin	3.41%	3.28%	-7.04%	14.18%	10.11%	-0.32%
Effective Tax Rate	-	-	-	16.28%	10.90%	11.92%
EBITDA	244.95	267.6	210.77	220.5	190.42	200.47
EBITDA Margin	10.85%	11.85%	9.24%	16.75%	14.98%	15.83%
Depreciation & Amortization	250.15	250.68	258.8	99.29	94.85	85.21
EBIT	-5.2	16.92	-48.03	121.2	95.57	115.26
EBIT Margin	-0.23%	0.75%	-2.11%	9.21%	7.52%	9.10%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).